Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity

LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the...
October 29, 2025 11:00 ET | Source: Plum Tree Psychology

Plum Tree Launches New Chronic Illness Therapy Program

Plum Tree Psychology a leading behavioral-health practice in the Fox Valley, has announced the launch of its new Chronic Illness Therapy Program.
October 28, 2025 08:00 ET | Source: Cingulate Inc.

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products...
October 23, 2025 16:45 ET | Source: Cingulate Inc.

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products...
October 15, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Biofeedback Instrument Market Size/Share Worth USD 340 Million by 2034 at a 6.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biofeedback Instrument Market Size, Trends and Insights By Product Type (EMG...
October 14, 2025 08:00 ET | Source: Cingulate Inc.

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS...
October 08, 2025 12:00 ET | Source: Unyte Health

Unyte Health Celebrates 10 Years as the Leader in Nervous System Regulation and Sound-Based Listening Therapies

Unyte Health marks 10 years as the leader of evidence-based listening therapies that support nervous system regulation, resilience, and mind-body wellness.
September 17, 2025 08:45 ET | Source: Cingulate Inc.

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

KANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
September 11, 2025 21:00 ET | Source: Armstrong Industrial Corporation Limited

Armstrong Asia Signs MOU with Checkmate Capital Group to Explore Strategic Collaboration

SINGAPORE, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Armstrong Asia, a leading Singapore-based manufacturer of flexible material solutions with 16 factories across 7 countries in Asia, has signed a...
August 19, 2025 08:45 ET | Source: Cingulate Inc.

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19,...